Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 2,339 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,339 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total value of $38,593.50. Following the sale, the insider now directly owns 176,952 shares in the company, valued at $2,919,708. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, September 3rd, Soleil Boughton sold 2,345 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.65, for a total value of $34,354.25.
• On Tuesday, August 6th, Soleil Boughton sold 2,334 shares of Hims & Hers Health stock. The stock was sold at an average price of $17.30, for a total transaction of $40,378.20.
• On Tuesday, July 23rd, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.29, for a total transaction of $47,377.15.
• On Tuesday, July 9th, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.28, for a total value of $47,353.80.

Hims & Hers Health Stock Down 1.1 %

Hims & Hers Health stock opened at $16.10 on Wednesday. The company has a market capitalization of $3.46 billion, a PE ratio of -1,610.00 and a beta of 1.05. The firm’s fifty day moving average is $17.62 and its 200 day moving average is $17.05. Hims & Hers Health, Inc. has a 12-month low of $5.65 and a 12-month high of $25.74.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The company had revenue of $315.65 million for the quarter, compared to analysts’ expectations of $302.43 million. During the same quarter in the prior year, the firm earned ($0.03) EPS. The business’s revenue was up 51.8% on a year-over-year basis. Sell-side analysts expect that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Truist Financial boosted their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 18th. Bank of America decreased their price objective on Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating for the company in a report on Friday, September 13th. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Jefferies Financial Group raised their price objective on Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, June 27th. Finally, TD Cowen upped their target price on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Eight equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, Hims & Hers Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.86.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its holdings in shares of Hims & Hers Health by 113.1% during the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after buying an additional 3,205,108 shares during the last quarter. Farallon Capital Management LLC lifted its position in Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after acquiring an additional 1,634,000 shares in the last quarter. M&G Plc acquired a new position in Hims & Hers Health during the 1st quarter valued at about $8,232,000. State of Michigan Retirement System increased its holdings in Hims & Hers Health by 177.8% during the 2nd quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock worth $10,095,000 after purchasing an additional 320,000 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Hims & Hers Health by 67.5% in the second quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock worth $13,701,000 after purchasing an additional 273,473 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.